Stockwinners Market Radar for August 08, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:40 EDT Cathie Wood's ARK Investment bought 210K shares of Teladoc today

20:38 EDT Cathie Wood's ARK Investment bought 246K shares of Twilio today

19:25 EDT Berkshire Hathaway increases Occidental Petroleum stake by $390.7M - In a regulatory filing, Occidental Petroleum disclosed that its major shareholder Berkshire Hathaway bought 6.68M shares of common stock in a total transaction size of $390.7M on August 4th.

18:25 EDT Oshkosh CEO: We have a record backlog - In an interview on CNBC's Mad Money, John Pfeifer said Oshkosh has a record backlog and order rates are very strong. The company is having some supply chain disruptions that are creating manufacturing inefficiencies, but it is "working aggressively" to resolve them. Pricing will catch up with inflation over time, he added. The company's technology investments are driving it forward, he noted. It plans to invest more than $300M in electrification over the next four years.

18:12 EDT Corvex Management discloses 5% stake in MDU Resources - Corvex Management disclosed a 5% stake in MDU Resources, which represents over 10.14M shares. The filing does allow for activism.

18:00 EDT Pzena Investment reports AUM as of July 31 at $47.2B vs. $45.0B as of June 30

17:51 EDT Enthusiast Gaming updates senior management team, names John Albright chairman - Enthusiast Gaming provided the following update on its senior management team and board of directors. As previously announced, current CEO, Adrian Montgomery will remain in his role as CEO until such time that a successor is named, at which point he will transition to chair of the board of directors. A search committee has been established to find Adrian's successor. Current SVP of global sales, Bill Drolet is being appointed chief revenue officer and will oversee all programmatic and direct revenue, customer success, and marketing. Drolet joined Enthusiast Gaming in 2020 and has been a leader for the company, building out its global direct sales organization. JB Elliott will be joining the company as SVP, legal and general counsel. In this role, Elliot will oversee the company's ongoing legal strategy and provide legal counsel across all matters related to the company's commercial business, ethics and compliance, and governance. Prior to joining Enthusiast Gaming, JB was a senior associate at Stikeman Elliott with a practice focusing on corporate and commercial law, including national and cross-border mergers and acquisitions, capital markets, securities, joint ventures, and corporate finance. Current lead director, John Albright has been appointed chair of the board. Albright has served on the board of Enthusiast Gaming since 2021.

17:46 EDT Horizon Global announces review of strategic alternatives - Horizon Global announced that the company's Board of Directors has authorized the review of strategic alternatives to enhance shareholder value. Such strategic alternatives could involve a sale of a portion or the entirety of the business. "Our objective is to maximize shareholder value," stated Horizon Global's Board Chair John Kennedy. "We have received inbound interest in the company and, given this level of interest, the Board has made the decision to review strategic alternatives. We believe there is significant value tied to our best-in-class products, iconic brands and deep customer relationships." The company noted that there can be no assurance that the Board's review process will result in any transaction or other alternative. There is no set timetable for the strategic review process and Horizon Global does not intend to provide updates unless or until the Board approves a specific action or otherwise determines that disclosure is appropriate or necessary.

17:31 EDT National Healthcare announces $25M stock repurchase authorization - National HealthCare announces that its Board of Directors, at a regularly scheduled meeting, has authorized a new stock repurchase program. The program will allow for repurchases of up to $25M of its common stock. The new stock repurchase plan will begin August 11, 2022 and will expire on August 10, 2023.

17:22 EDT Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056 - Mersana Therapeutics (MRSN) announced a global collaboration that provides GSK (GSK) an exclusive option to co-develop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2. XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells."GSK brings highly complementary development and commercial capabilities, a wealth of immuno-oncology experience, a deep knowledge of the STING pathway and a shared vision for XMT-2056's broad potential," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "We believe this agreement solidifies Mersana's position as a partner of choice during this momentous period in the ADC space and serves as validation for our Immunosynthen platform, which takes ADCs beyond the cytotoxic realm by enabling a targeted stimulation of the innate immune system. Additionally, the agreement structure demonstrates our ability to generate meaningful non-dilutive capital upfront to support the development of our innovative candidates while also providing the potential for meaningful downstream economics." In preclinical models, XMT-2056 demonstrated robust anti-tumor activity as a monotherapy in both HER2-high and HER2-low expressing models, and enhanced efficacy has been shown when used in combination with multiple approved agents, including trastuzumab, pertuzumab, anti-PD-1, or trastuzumab deruxtecan. Preclinical data also suggest that XMT-2056 has the potential to enable immunological memory for prolonged anti-tumor activity. Mersana expects to initiate a Phase 1 clinical trial of XMT-2056 to investigate its potential in a range of HER2-expressing tumors such as breast, gastric and non-small-cell lung cancers. The U.S. Food and Drug Administration recently granted an orphan drug designation to XMT-2056 for the treatment of gastric cancer.Under the terms of the agreement, Mersana will receive an upfront option purchase fee of $100M. Mersana also is eligible to receive up to $1.36B in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option.

17:04 EDT Groupon falls 6.9% to $12.92 after Q2 results and withdrawal of FY22 guidance

17:02 EDT Lemonade jumps 11% to nearly $28 after Q2 report

17:01 EDT Take-Two delays 'Marvel's Midnight Suns' to fiscal 2023 - Take-Two (TTWO) said in its quarterly report that its upcoming tactics game "Marvel's Midnight Suns" has been delayed to fiscal 2023 from October 2022. The game is set to release on PlayStation 4 (SONY), PS5, Xbox One (MSFT), Xbox Series X/S, PC, and Nintendo Switch (NTDOY).

16:52 EDT Canoo sees second half of FY22 operating expenses $200M-$245M - Sees second half of FY22 Capital Expenditures $100M-$125M.

16:46 EDT Novavax drops 30% to $39.59 after cutting FY22 revenue outlook

16:41 EDT Babcock & Wilcox positioned for 'milestone' 2022

16:40 EDT Voya Financial CFO Smith to leave company - Voya Financial announced that Michael S. Smith, vice chairman and chief financial officer, has decided to depart the company to pursue expanded leadership roles outside of Voya. Smith will continue to serve as Voya's CFO through Nov. 15, 2022, overseeing the close and reporting of the company's third quarter, which ends Sept. 30, 2022. The company will conduct an internal and external search to identify Smith's successor. "On behalf of our board and our entire leadership team, I would like to thank Mike for his significant leadership contributions to Voya during the past 13 years," said Rodney O. Martin, Jr., chairman and chief executive officer, Voya Financial, Inc. "As our CFO, and previously as a business leader and our chief risk officer, Mike has played a vital role in Voya's business transformation. He has contributed to the strong results that we have achieved, the culture that we have fostered and the value that we have delivered to shareholders. We are grateful to Mike and his family - and we wish them the very best going forward."

16:37 EDT Ramaco Resources sees FY22 CapEx $105M-$125M - The company said, "We have increased our growth-related capital expenditure guidance by roughly $25 million, and now expect total 2022 capital expenditures of $105 - $125 million. This increase reflects the expenditure for the Maben acquisition, the expansion of the Elk Creek processing capacity, as well as the acceleration of various equipment related capital expenditures for enhanced production from 2022 to 2023. We are reducing our full-year 2022 production guidance to 2.8 - 3.1 million tons due to the previously announced methane ignition at one of the three mines at our Berwind mine complex. We have also increased our cost guidance to $89 - $97 per ton, reflecting lower expected second half tonnage from Berwind, as well as the combination of continued inflationary increase on labor and some mine costs."

16:35 EDT Zealand Pharma AS (ADS) trading resumes

16:35 EDT Mersana Therapeutics trading resumes

16:31 EDT Novavax trading resumes

16:28 EDT Superior Group began transition of key leadership positions in Q2 - During the second quarter, the Company began the transition of key leadership positions as previously communicated with the addition of Catherine Beldotti Donlan, President of Healthcare Apparel and Mike Koempel, CFO. "The transition has been seamless with the support of Peter Benstock serving as a healthcare apparel advisor and Andy Demott, former Chief Financial Officer, continuing to serve as Chief Operating Officer. The Company also added management expertise in supply chain, distribution and division management to support its long-term growth objectives," the company said. "In order to further position for growth, we re-aligned the Company along three business segments: Healthcare Apparel, Branded Products and Contact Centers," said Michael Benstock, CEO of the Company. "This re-alignment enables a more singular focus on healthcare, the ability to capitalize on synergies across all branded product offerings and a continued focus on driving significant growth in our contact centers. Overall, while we were pleased with our revenue growth this quarter, we recognize the ever-evolving macro environment and emerging challenges of rising interest rates and historic levels of inflation. As a result, we are taking a disciplined and prudent approach to cash management and have begun to implement cost initiatives of at least $8 million in annualized savings, while still maintaining our focus on consistent sales growth."

16:27 EDT Precigen expectsTrans Ova Genetics sale to close in Q3 - "The transaction to sell Trans Ova Genetics, which is expected to close in Q3 2022, will provide Precigen with $170M in cash up-front and up to a $10M earn-out over the next two years. The proceeds from this sale will fortify our balance sheet and provide non-dilutive funds to pay our convertible notes, which we intend to do when due," said Harry Thomasian Jr., CFO of Precigen. "We believe that our cash on hand and cost reduction initiatives, taking into account our plan for our convertible notes, give us enough runway to advance our clinical priorities into Q4 2023."

16:21 EDT Invacare suspends FY22 guidance - Given the continuing supply chain challenges, the company has suspended its full year 2022 financial guidance. The company will provide updates to the market as the year progresses on the planned deployment of recently announced funding, and as circumstances evolve. The company continues to focus on its transformation plan, revenue growth for clinically relevant product categories, and effectiveness of pricing actions to drive significant improvement in financial performance to deliver enhanced long-term shareholder value.

16:19 EDT Zealand Pharma announces voluntary delisting of ADSs from Nasdaq in U.S. - Zealand Pharma A/S announced it has given formal notice to Nasdaq of the company's intention to voluntarily remove its American Depositary Shares, or ADSs, from listing on the New York-based Nasdaq Global Select Market. One ADS currently represents one ordinary share in Zealand Pharma, and today the company's ADSs account for less than 1.5% of the total share capital. The company's ordinary shares will continue to be listed on Nasdaq Copenhagen, which is the primary source of liquidity and trading flexibility for Zealand shares. According to public filings, approximately 80% of institutional investors holding Zealand's ordinary shares listed on the Nasdaq Copenhagen are based outside of Denmark, including in the U.S., underscoring its viability for global investors. Zealand has been listed on the Nasdaq Copenhagen since November 2010 under the ticker ZEAL.CO and trades in DKK. The company subsequently listed its ADSs on the Nasdaq Global Select Market in the U.S. in August 2017 under the ticker ZEAL and trades in USD. "By consolidating trading in Zealand stock on the Nasdaq Copenhagen, we believe we can provide improved liquidity and flexibility of trading for global investors, while allowing us to streamline operating efficiency and reduce corporate costs in line with our strategy to prioritize our resources on R&D," said Adam Steensberg, CEO of Zealand Pharma. "We are an international biotech company committed to delivering value to shareholders and solutions to patients as we advance our pipeline of innovative peptide therapeutics to address metabolic and gastrointestinal diseases."

16:18 EDT Turtle Beach concludes proactive outreach to potential buyers - Turtle Beach provided an update regarding its previously announced review of strategic alternatives. Over the course of the review, the Board's Strategic Committee, in consultation with its financial and legal advisors, engaged in a proactive process to evaluate strategic opportunities, focused on a sale of the Company. As part of the review, the Strategic Committee, through its financial advisor, Bank of America, contacted and held discussions with 109 parties, which included strategic and financial parties. The Strategic Committee received robust interest from multiple strategic parties, however, due to a number of factors including current market dynamics, the challenging financing environment, inflation affecting consumer discretionary spending and ongoing integrations of prior acquisitions, these parties were ultimately not in a position to move forward with an acquisition at this time. Furthermore, while several financial parties submitted preliminary indications of interest to acquire the Company, in light of factors including current market dynamics and the challenging financing environment, those parties declined to move forward in the process. Therefore, the Strategic Committee has determined to conclude the proactive outreach to potential buyers. Nevertheless, the Strategic Committee will continue to evaluate strategic opportunities consistent with the Strategic Committee's charter. "Through the duration of our extensive process, the Board and Strategic Committee were singularly focused on maximizing value for Turtle Beach stockholders," said Mr. William Keitel, Chair of the Strategic Committee. "We have conducted a robust and exhaustive review of strategic alternatives, focused on a potential sale of the Company, contacting over 100 potential acquirors, but these parties were not able to make a proposal that would deliver value to our stockholders due to a convergence of external factors, including macro-economic challenges related to supply chain constraints, inflationary concerns and a challenging consumer spending environment. As a result, we ultimately determined to stop proactive outreach to potential buyers but will continue to consider opportunities consistent with the Strategic Committee's charter. We continue to believe in the strong prospects for Turtle Beach in the large gaming market in which we operate and we remain focused on driving value for stockholders as a standalone business."

16:08 EDT Cyteir Therapeutics expects cash to fund operations into second half of 2024 - Cash and cash equivalents as of June 30, 2022 were $166.4 million. As a result of updates from the CYT-0851 program review and postponing CYT-1853 development, cash and cash equivalents are now expected to fund planned operations into the second half of 2024, which is longer than we previously forecasted.

16:07 EDT DigitalOcean CFO Sorenson to retire in 2023 - DigitalOcean announced that Chief Financial Officer Bill Sorenson plans to retire from the Company in 2023 and that it will commence a search for his successor. Mr. Sorenson will continue in his capacity throughout the search process and then will serve as an advisor to the company until his departure in August 2023 ensuring a smooth transition and onboarding of a new chief financial officer.

16:00 EDT Novavax trading halted, news pending

16:00 EDT Upstart Holdings trading halted, news pending

16:00 EDT AMTD Digital Inc trading resumes

14:29 EDT Amgen says tarlatamab showed 'encouraging antitumor activity' in Phase 1 study - Amgen announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager molecule targeting delta-like ligand 3, in small cell lung cancer, or SCLC. Updated data from the ongoing Phase 1 study were presented at the International Association for the Study of Lung Cancer, or IASLC, 2022 World Conference on Lung Cancer, or WCLC. In heavily pretreated patients with SCLC, a population with few treatment options beyond first-line, investigational tarlatamab demonstrated encouraging antitumor activity with notable response durability. Tarlatamab delivered a confirmed ORR of 23%, confirmed and unconfirmed responses, a median duration of response of 13.0 months and a median overall survival, or OS, of 13.2 months. Treatment-related adverse events of any grade occurred in 97 patients, or 92%, and TRAEs grade greater than or equal 3 occurred in 33 patients, or 31%. Based on these data, a potentially registrational Phase 2 study of tarlatamab in the third-line treatment of SCLC is currently enrolling patients. Additional studies investigating tarlatamab are underway, including DeLLphi-303, a Phase 1b study testing tarlatamab in combination with standard of care in first-line SCLC and a Phase 1b study in de novo or treatment-emergent neuroendocrine prostate cancer.

13:03 EDT Eastern Insurance Group acquires assets of John T. Burns Insurance Agency - Eastern Insurance Group announced that it has acquired the operating assets of the John T. Burns Insurance Agency, Inc, a full-service insurance agency located in Newtonville, MA. The transaction is effective August 1, 2022 and marks the 36th acquisition of an independent insurance agency by Eastern Insurance since 2002 and its second this year.

12:47 EDT U-Haul opens company-owned facility in Sebring - U-Haul recently purchased the former Starpar Storage property at 4541 Tanglewood Drive for its first company-owned facility in Sebring, Florida to better meet the moving and self-storage demands of Highlands County. U-Haul Moving & Storage of Sebring began operations on July 19 and is now offering self-storage with extended-hours access. Customers will also have access to truck and trailer sharing, towing equipment, moving supplies and boxes, professional hitch installation and much more. The property currently houses 575 rental units.

12:01 EDT Palantir falls -12.0% - Palantir is down -12.0%, or -$1.38 to $10.07.

12:01 EDT AMTD Digital falls -21.0% - AMTD Digital is down -21.0%, or -$151.23 to $570.00.

12:00 EDT Blue Apron rises 17.8% - Blue Apron is up 17.8%, or 53c to $3.51.

11:49 EDT Lyft launches Lyft Media division - In a blog post, Lyft announced Lyft Media, a media and advertising business. The company said, "As more people resume their daily travel, we've built a suite of new products to allow advertisers to engage with this growing audience throughout their transportation journeys...Lyft Halos are smart digital rooftop screens that capture attention with engaging videos targeted to the vehicle's exact location and time. Brands can reach mass audiences at the specific times and places most relevant to their business, and track the performance of their campaigns through our attribution partners...These rooftop screens are available in New York City, Los Angeles, and Washington D.C., with more cities coming soon...Lyft's in-car tablets are seamlessly integrated with the rideshare experience. Riders can track progress along their route, rate and tip drivers, and control the music of their ride through our partnership with iHeartRadio - all directly from the tablet. Brands can serve dynamic content to a highly engaged rideshare audience for the duration of the ride...We're expanding in-car tablets in Los Angeles, Chicago, San Francisco, and Washington D.C. We plan to have tablets present in 25% of all rides on the Lyft platform in these markets, reaching millions of riders by the end of the year...Lyft operates the largest bikeshare network in the country... With stations located throughout our cities, our bikeshare station ad panels and docks provide incredible street-level media opportunities at highly-trafficked locations in each city. As we continue to roll out our next-gen e-bikes, we will also be upgrading our stations to include digital ad panels...Lyft Skins allows advertisers to engage the rideshare audience with our most powerful digital channel - the Lyft App itself. Brands can reach our almost 20 million active riders with a customizable branded icon and banner." Reference Link

11:08 EDT American Power Group, Galileo Technologies US enter marketing collaboration - American Power Group and Galileo Technologies US jointly announce their plan to leverage their complementary alternative fuel capabilities and pursue business opportunities together which can lower net fuel costs and reduce carbon emissions for their customers.

11:05 EDT Vaccinex announces publication of results of Phase 2 SIGNAL study - Vaccinex announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington's Disease were published in the August 8, 2022 issue of Nature Medicine. In parallel, a second report has been published in the Journal of Neuroinflammation2 detailing the pathologic impact of SEMA4D on neuroinflammatory cells in both HD and Alzheimer's disease. The Nature Medicine article, titled "Pepinemab antibody blockade of SEMA4D in early Huntington's Disease: a randomized, placebo-controlled, Phase 2 trial," provides a comprehensive analysis of results from the Phase 2 study showing that while the trial did not meet its pre-specified primary efficacy endpoints, brain imaging measures showed a significant reduction in atrophy of the brain caudate nucleus and prevented loss of metabolic activity in most brain regions. Multiple other exploratory and post-hoc assessments indicate a cognitive benefit to treatment. Pepinemab was well-tolerated by participants in the trial. The Journal of Neuroinflammation article, titled "Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity," demonstrates that SEMA4D is upregulated on neurons that are stressed or damaged during HD and AD disease progression and this triggers physiological changes in astrocytes that reduce their ability to facilitate energy metabolism in the brain and to control levels of neurotransmitters required for efficient signaling. Experiments in an animal model of Alzheimer's disease demonstrate that treatment with SEMA4D-blocking antibody inhibits reactive transformation of astrocytes, restores neuronal transmitters, and prevents or reduces cognitive deficits. These findings encourage continued development of pepinemab as a potential therapy for patients with early manifest symptoms of HD and potentially AD. Accordingly, a phase 1b/2a study of pepinemab in Alzheimer's disease has been initiated and is actively enrolling patients. The mechanism of action of pepinemab, targeting neuroinflammation, may provide an alternative to other AD therapies that target aggregates of Abeta amyloid. Summary of Key Findings from the SIGNAL HD trial Highlighted in the Nature Medicine Article: The Nature Medicine article highlights results that support the potential of pepinemab as a novel therapeutic approach for treating cognitive impairment in patients with HD, particularly those initially presenting with mild cognitive deficits. Key Findings from the Phase 2 SIGNAL HD trial include: significantly improved cognition in patients with early manifest disease, as reflected in the HD-Cognitive Assessment Battery of 6 different cognitive measures; significantly reduced apathy severity (p=0.02), measured by the Problem Behaviors Assessment which has previously been reported to correlate with cognitive decline. reduced atrophy in the caudate nucleus, a brain region known to undergo early degeneration in HD. significantly improved brain metabolic activity as detected by FDG-PET in the majority of brain regions examined. FDG-PET signal has been reported to correlate with cognitive decline and clinical progression in AD. was well-tolerated with a low frequency of treatment-emergent adverse events and a low treatment discontinuation rate over the 18-month treatment period. SIGNAL was a phase 2, multi-center, randomized, double-blinded, placebo-controlled clinical trial in 265 subjects including 179 early manifest and 86 late prodromal subjects all confirmed to carry the Huntington's disease mutation. Subjects were randomized 1:1 for monthly intravenous infusion with either 20 mg/kg pepinemab or placebo for at least 18 months at 32 centers in the U.S. and Canada. The study is now complete, and we believe the program is Phase 3-ready.

10:33 EDT Zhong Yang Financial Group Ltd trading resumes

10:23 EDT Zhong Yang Financial Group Ltd trading halted, volatility trading pause

10:00 EDT AMTD IDEA Group falls -14.1% - AMTD IDEA Group is down -14.1%, or -66c to $4.02.

10:00 EDT AMTD Digital falls -23.3% - AMTD Digital is down -23.3%, or -$168.23 to $553.00.

10:00 EDT AMC Entertainment rises 16.9% - AMC Entertainment is up 16.9%, or $3.74 to $25.92.

09:47 EDT Zweig Total Return Fund falls -7.4% - Zweig Total Return Fund is down -7.4%, or -67c to $8.34.

09:47 EDT Palantir falls -12.2% - Palantir is down -12.2%, or -$1.40 to $10.05.

09:47 EDT Sunnova Energy rises 12.6% - Sunnova Energy is up 12.6%, or $3.48 to $31.06.

09:41 EDT Athersys reports preclinical results of MultiStem radiation countermeasure study - Athersys announces results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute, or AFRRI, a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem administration provided benefit in an animal model of acute radiation syndrome, or ARS. The results demonstrate that the administration of MultiStem cells increased survival in treated animals compared to vehicle treatment, resulted in higher body weights in surviving animals and positive trends in recovery of the hematopoietic system, the company stated. "In general, this research has demonstrated the potential for MultiStem treatment to improve survival and recovery following radiation injury," the company said. "This program represents another positive step in a broader development strategy to investigate the use of MultiStem in addressing severe critical care injuries and diseases," said Dan Camardo, CEO of Athersys. Dr. Robert W. Mays, Executive Vice President and Head of Regenerative Medicine & Neuroscience Programs of Athersys, added: "Based on this study and prior research, we believe that MultiStem therapy has the potential to provide benefit to victims of ARS as well as other immune and neurological disorders. We look forward to exploring opportunities to move this important program forward."

09:41 EDT Reata Pharmaceuticals trading resumes

09:39 EDT Tyson Foods: Demand for chicken 'extremely strong'

09:38 EDT MEGL Stock trading resumes

09:36 EDT GameStop trading halted, volatility trading pause

09:34 EDT WidePoint's IT Authorities awarded $2.6M three-year contract - WidePoint announced that its subsidiary IT Authorities has been awarded a new Managed Service Provider contract by a leading U.S. beverage bottler. The contract is for three years with a total contract value of $2.6 million.

09:32 EDT Cushman & Wakefield acquires Burbage Realty Partners Limited - Cushman & Wakefield has acquired specialist UK logistics and industrial consultancy Burbage Realty Partners Limited as it continues its expansion in the growth sector. Founded in 2017, BRPL provides a suite of services including strategic land, development funding, investment, lease advisory and occupational agency. Operating across the UK and a leader in the Midlands Grade A logistics market - a critical location for distribution centers and online retail fulfilment - its clients include many of the sector's foremost developers and investors. The strategic acquisition complements and strengthens Cushman & Wakefield's UK Logistics & Industrial team, headed by Richard Evans, which has a strong occupier and investor client base. It also builds on the firm's expansion of its sector teams across Europe through a succession of senior hires in key markets including Germany and Spain. The acquisition will see eight new colleagues joining Cushman & Wakefield. Among these, Cameron Mitchell, George Underwood, and James Harrison will join as International Partners, while Franco Capella, Mark Thomas and Tom Kimbell join as Partners and Sophia Cooper as an Associate. The team will continue to be based at its current office in Northampton, while being integrated into Cushman & Wakefield's national sector team. They will work closely with other senior figures in the logistics team, including David Binks, Head of Cushman & Wakefield's Logistics & Industrial team in the Midlands. BRPL is owned separately to Burbage Realty Limited. The latter, founded in 2003 by John Burbage as a UK logistics and industrial property consultancy, is unaffected by this acquisition and remains an independent business under the ownership of Burbage Capital Limited

09:26 EDT Merit Medical launches SafeGuard Focus Cool Compression Device - Merit Medical Systems announced the launch of its SafeGuard Focus Cool Compression Device, an innovative addition to its SafeGuard platform. It is part of a broader cardiac portfolio that offers products and accessories necessary for cardiac rhythm management, electrophysiology, and lead extraction procedures as well as interventional cardiac resynchronization therapy. The new compression device builds upon the original SafeGuard Focus, a revolutionary idea that provides compression over closed surgical sites which can assist hemostasis in patients with pacemaker and implantable cardioverter defibrillator pockets. The SafeGuard Focus Cool offers the same high performance but with an easy-to-prepare cooling solution that does not require refrigeration, making it ideal for the lab environment.

09:23 EDT Nvidia falls 6.9% to $176.74 after negative Q2 revenue pre-announcement

09:17 EDT FuboTV announces unscripted content deal with Maximum Effort Productions - Maximum Effort Productions, a production company co-founded by Ryan Reynolds and George Dewey in 2018, and FuboTV announced a first-look deal for unscripted content. As part of the deal for an exclusive first-look for unscripted TV series, Maximum Effort will launch Maximum Effort Network, a linear channel on FuboTV, and will also have a blind scripted deal with FuboTV. Maximum Effort Productions has been granted creative control over the channel's content. All advertising sales for the Maximum Effort channel will be managed by FuboTV. Under the terms of the agreement, Maximum Effort will receive equity from FuboTV as consideration for the deal. Maximum Effort Productions will maintain its three-year first-look development deal with Paramount Pictures announced in May of 2021 for feature projects.

09:15 EDT Sandvik acquires precision tools manufacturer Sphinx Tools, no terms disclosed - Sandvik has signed and completed an agreement to acquire 100% of the equity interests in the Switzerland-based Sphinx Tools Ltd and its wholly owned subsidiary P. Rieger Werkzeugfabrik AG. Sphinx Tools' offering primarily consists of precision solid round tools (micro tools) and surgical cutting tools. The customers are mainly within the automotive, aerospace and medical segments. The company will be reported within Sandvik Coromant, a division within Sandvik Manufacturing and Machining Solutions. Sphinx Tools was founded in 1994, has around 115 employees and is based in Switzerland. In 2021, the company generated revenues of approximately 292 MSEK. The EBITA margin is neutral to Sandvik Manufacturing and Machining Solutions. Impact on Sandvik's earnings per share will be limited, yet slightly positive. The parties have agreed not to disclose the purchase price.

09:12 EDT Focus Treasury and Credit Solutions partners with Community Capital - Focus Financial Partners announced that its subsidiary, Focus Treasury and Credit Solutions has partnered with Community Capital Technology to offer the FTCS Loan Marketplace exclusively to Focus partner firms and their advisors. The Marketplace will provide an efficient way for advisors to connect their clients with a range of banks and other lenders to source credit solutions. The Marketplace will be available through FTCS' credit portal and will provide access to Community Capital's proprietary online loan marketplace via its digital platform. FTCS facilitates access to cash management and lending alternatives for personal, commercial and nonprofit needs, equipping the advisors of Focus partner firms with private banking credit tools. Community Capital offers a nationwide network of more than 1,200 banks, credit unions, insurance companies, credit funds and other financial institutions, which will substantially expand FTCS' access to credit providers. The Marketplace will enhance advisors' ability to help their high and ultra-high net worth clients meet their bespoke credit needs. It will also promote competitive pricing and terms for their clients' general borrowing needs.

09:10 EDT Veeco releases 2021 sustainability report - Veeco Instruments released its 2021 sustainability report highlighting the company's environmental, social, and governance, ESG, initiatives. In particular, the third annual report spotlights Veeco's progress towards their ESG goals released earlier this year. "I think of 2021 as an inflection point for Veeco," said Bill Miller, Veeco's Chief Executive Officer. "We completed a company-wide transformation and are now squarely focused on executing our growth strategy and strengthening our commitment to ESG. Our vision is to enable a future where technology improves the human experience, and we recognize that achieving our vision is dependent, in part, on our corporate sustainability efforts. Our first set of ESG Goals, released earlier in 2022, was an important milestone on our sustainability journey, and we are excited to share our progress in this 2021 report."

09:09 EDT Datasea announces eight new orders for its Smart Push 5G messaging solution - Datasea is a digital technology corporation engaged in three converging and innovative business segments: 5G messaging, acoustic intelligence, and smart city technology in China. Today, the Company announced that Shuhai Zhangxun Information Technology, a subsidiary of the Chinese operating company contractually controlled by the Company, has received eight new purchase orders from companies including Hangzhou Yuefan Culture and Art. Shuhai Zhangxun will provide Smart Push. Due to the needs and requirements for precision marketing solution at an attractive rate, Smart Push is becoming a standard. Datasea has continued to press forward with the multiple channels such as direct sales and sales partners to secure new clients, and there has been a major increase in interest in the Smart Push. Commenting on today's announcement, Zhixin Liu, CEO of Datasea, stated, "Our 5G messaging business continues to expand and is accelerating. We are excited to add these respected customers and deliver solutions to help them with client acquisition and business growth. Benefiting from our sales model, we are able to deliver a robust pipeline of innovation aligned to what consumers are looking for and keep driving growth."

09:09 EDT Advent Technologies and DEPA Commercial, sign MoU for hydrogen projects - Advent Technologies Holdings, Inc., an innovation-driven leader in the fuel cell and hydrogen technology space, announced the signing of a Memorandum of Understanding with DEPA Commercial , importer of pipeline gas and liquefied natural gas in Greece to enter into a strategic collaboration on hydrogen projects of common interest. The MoU sets out the framework for a forthcoming mutually binding agreement. The parties have preliminarily agreed to the following actions: Collaborate on the production of environmentally friendly hydrogen as a fuel with the participation of other major industrial partners. Co-develop a proprietary and highly differentiated CHP system ready for mass production with efficiency approaching 90% and with multi-fuel operating capabilities that can address the key current, future, and on-grid, off-grid operation modes and business cases. Create an innovation hub for the Greek hydrogen and fuel cell industry and develop synergies for promoting hydrogen and related technologies. DEPA's CEO, Dr. Konstantinos Xifaras, stated: "Our cooperation with Advent marks another important milestone in the advancement of hydrogen technologies in our country. DEPA has been closely following and actively pushed for the developments in the hydrogen sector, while Advent has extensive electrochemistry and engineering expertise and a global scale of operations and manufacturing footprint. We look forward to working with Advent's team of experts, contributing to the diversification of the national energy mix and the security of the energy supply while simultaneously strengthening the national economy."

09:08 EDT Avalon GloboCare announces publication featuring QTY Code technology - Avalon GloboCare announced a new publication featuring the Company's QTY protein code technology in Chemical Reviews. The publication, entitled "Protein Design: From the Aspect of Water Solubility and Stability," focuses on the innovative QTY protein design code-co-developed by Avalon-as a novel platform to generate water-soluble proteins for a wide spectrum of biomedical applications. The publication provides a comprehensive review of the QTY protein code design platform. The QTY code design approach may have the potential to facilitate the 1) development of important drug modalities including monoclonal antibodies, 2) creation of water-soluble proteins from insoluble proteins that are important but difficult to work with drug targets, 3) evolution of computational methods for rational drug design, 4) development of novel therapeutic targets for pharmaceutical and cellular medicines, and 5) production of other important biomedical applications. "We are excited to have the technology we developed together with MIT's Dr. Zhang featured in this publication," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. "Over the past 70 years, there has been rapid advancement in the understanding of how biology works at the molecular level. Our QTY protein design code extends this knowledge, enabling an even more precise understanding and manipulation of protein structures and function. Not only does the QTY code contribute significantly to the knowledge base of an important class of proteins, but we believe it also provides new pathways for further investigation and subsequent applications that were previously unattainable. Importantly, we believe this publication is a validation of Avalon's strategy. We previously licensed patents from MIT related to the use of QTY solubilized membrane proteins to be used as decoy receptors in therapeutics. We subsequently filed additional patent applications jointly with MIT, and plan to apply for more patents with the university related to the QTY protein design technologies."

09:07 EDT AvidXchange announces TimberScan Titanium integration - AvidXchange Holdings announced TimberScan Titanium, now integrated with AvidPay, is available to Sage Intacct users offering a complete purchase-to-pay solution for professionals in the construction industry.

09:06 EDT Verizon Frontline Response Team deploys nearly 1,000 solutions this year - With more than 60 wildfires actively burning in more than a dozen states, the Verizon Frontline Response Team continues to deploy mission-critical communications technology in support of public safety agencies and the nearly 10,000 wildland firefighters currently on the front lines. This year alone, the Verizon Frontline Response Team has deployed nearly 1,000 Verizon Frontline solutions to first responders in 18 states including Alaska, North Carolina, Florida, California, Texas and New Mexico. Verizon Frontline technology has been delivered to multiple interagency command posts and 39 public safety agencies operating in nearly 70 communities. This technology provides mission-critical voice and data service to incident managers and firefighters operating in remote areas and helps coordinate fire mitigation efforts. The Verizon Frontline solutions provided by the Verizon Frontline Response Team have included Satellite Picocells on Trailers (SPOTs), routers, network extenders, mobile hotspots, smartphones and more.

09:05 EDT Kaltura adopts limited duration stockholder rights plan - The Board of Directors of Kaltura announced that it has adopted a limited duration stockholder rights plan. The Company has become aware of the rapid accumulation of a significant amount of the common stock of the Company by K1 Investment Management, financial sponsor to the Company's competitor Panopto, and Panopto's unsolicited public letter indicating an interest in acquiring the Company, as disclosed in a Schedule 13D filed on July 28, 2022. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all stockholders of the Company and ensure that the Board remains in the best position to discharge its fiduciary duties to the Company and its stockholders. Under the plan, one preferred stock purchase right will be distributed for each share of common stock held by stockholders of record on August 22, 2022. Under certain circumstances, each right will entitle stockholders to buy one one-thousandth of a share of newly-created Series A Junior Participating Preferred Stock of the Company at an exercise price of $13.00. The Company's Board of Directors will be entitled to redeem the rights at $0.01 per right at any time before a person or group has acquired 10% or more of the outstanding common stock. The rights will expire on August 6, 2023, subject to the Company's right to extend such date, unless earlier redeemed or exchanged by the Company or terminated.

09:02 EDT WalkMe names Adriel Sanchez as Chief Marketing Officer - WalkMe announced the appointment of Adriel Sanchez as Chief Marketing Officer, reporting to CEO and Co-founder, Dan Adika. As CMO, Sanchez will lead the global marketing organization to promote the WalkMe brand, including the development and execution of the company's strategic priorities and campaigns, while partnering closely with the sales and product organizations to drive revenue. Sanchez joins WalkMe from Newsela, where he spent more than three years serving as CMO.

09:01 EDT Uber, The Body Shop expand partnership - Uber Technologies and The Body Shop announced the expansion of their partnership to include almost all of the beauty company's retail stores across the U.S. This expansion brings new locations to the Uber platform and allows consumers in new cities including Illinois, Nevada, Georgia, Pennsylvania and even Alaska and Hawaii, to shop for their favorite The Body Shop products through Uber Eats. This partnership builds on the 2020 launch that brought six pilot locations to the Uber Eats and Cornershop apps, offering products from across the company's haircare, body care and skincare lines. Beginning August 10, 75 of The Body Shop storefronts will make more than 2,000 of the beauty retailer's most popular items, including Shea Body Butter, Ginger Shampoo, and its Tea Tree range, available for purchase on the Uber Eats app and delivered, on-demand, to your doorstep. Uber One members benefit from $0 Delivery Fee on all The Body Shop orders with $15 minimum purchase.

08:55 EDT WeTrade to enter strategic partnership with Jiqing for monkeypox test kits sales - WeTrade completed a discussion of the strategic partnership with Jiqing Biomedical Technology. The companies will sign the official contract soon and Wetrade will assume the exclusive sale channel for Jiqing's monkeypox virus test kits globally. Jiqing, a medical company in China, has changed its development strategy to overseas markets.

08:42 EDT Gladstone Commercial announces $32.5M industrial portfolio acquisition - On August 5, 2022, Gladstone Commercial Corporation acquired a 246,000 square foot, two-property, industrial portfolio, with locations in Vineland, NJ, and Bridgeton, NJ, for a gross purchase price of $32.5 million at a GAAP capitalization rate of 7.2%. The portfolio, acquired in a sale/leaseback transaction, is 100% leased to Garden State Bulb Company and its affiliates, with fifteen years of remaining absolute NNN term. Garden State Bulb Company is an industry leader in packaged dormant live goods products for sale in the US market. The acquisition of this industrial portfolio is consistent with Gladstone Commercial's growth strategy of acquiring functional assets leased to credit-worthy tenants in strong industrial locations.

08:39 EDT One Equity Partners agrees to sell power generation business of UK's BRUSH Group - One Equity Partners announced that it has entered into a definitive agreement to sell the Power Generation business of BRUSH Groupto energy technology company Baker Hughes . Headquartered in Ashby de la Zouch, United Kingdom with roots dating back to 1876, BRUSH helps engineer and support a comprehensive range of power-related products and solutions including generators, condensers, motors, transformers, switchgear and control and monitoring systems. BRUSH's Power Generation business designs, assembles and services large scale generators that provide primary and standby electrical power to customers across the infrastructure, renewables, oil and gas and utilities sectors. "We are thrilled to help unlock meaningful value creation through the transformational sale of BRUSH's largest business segment. OEP recognized BRUSH as a leader within the Power Generation equipment and services sector when we acquired the business last year. We look forward to continuing to support and grow BRUSH's remaining Power Distribution & Networks business alongside its exceptional management team," said Steve Lunau, Managing Director at One Equity Partners.

08:38 EDT Navitas Semiconductor's technology powers OnePlus smartphone charger - Navitas Semiconductor has announced that its GaN power IC technology has been used by global mobile-technology company OnePlus for the 160 W in-box fast charger supplied with the company's latest OnePlus 10R 5G and OnePlus ACE 5G Android smartphones.

08:37 EDT Sarepta announces progress on MyoAAV program - Sarepta Therapeutics announced that following progress on its sponsored research agreement on the MyoAAV program, it has executed a license agreement with the Broad Institute of MIT and Harvard for MyoAAV in Duchenne muscular dystrophy and certain other neuromuscular and cardiac indications. The announcement follows confirmation by Sarepta's internal research and manufacturing teams of earlier published research from Broad Institute, which was conducted under a research agreement that began in 2020. MyoAAV is a new group of adeno-associated viruses that use a modified outer protein shell of AAV, known as the capsid, to deliver genetic therapies with greater efficiency and at lower doses. Data published in the journal Cell in 2021 found that, in mouse models of Duchenne muscular dystrophy and X-linked myotubular myopathy, MyoAAV demonstrated more efficient delivery of gene therapy and gene editing payloads, resulting in complete restoration of muscle function and improved survival. In preclinical data from non-human primates, compared to natural AAV serotypes, MyoAAV: Delivered 25-50 times greater gene expression in multiple skeletal muscles and 10-15 times greater gene expression in cardiac muscle; Demonstrated reduced delivery to the liver by 50 percent and showed lower accumulation in the liver; Can be used at up to a log lower dose than traditional AAV vectors, due to increased efficiency. "Research published by Broad Institute, and so far corroborated by Sarepta's own internal research, reinforces the potential of MyoAAV as a breakthrough next-generation approach in genetic medicine delivery," said Doug Ingram, president and chief executive officer, Sarepta. "The significantly improved efficiency of MyoAAV may unlock the ability to effectively deliver genetic medicine at as much as a log lower doses when compared to current AAVs, which could substantially reduce viral load and cost of goods in the future. As one of the leaders in the use of AAV-mediated genetic medicine to treat rare disease, we intend to push the science forward, and our license for MyoAAV is a quintessential example of that effort."

08:36 EDT Point Biopharma to host investor education event on August 18 - POINT Biopharma announced that next week, on Thursday, August 18, 2022 at 12:00 PM ET, the Company will be presenting a 45-minute educational webinar entitled "Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm". Topics to be presented at the webinar include: Overview of SPLASH trial design and rationale for hormone switches; What is a control arm benchmark, why PROfound1 & IMbassador2502 were selected as SPLASH benchmarks; Review current treatment patterns, including sequencing considerations, in real-world clinical settings for mCRPC patients. The webinar will feature presentations from two Thought Leaders: Dr. Oliver Sartor & Dr. Kim Chi. They will be joined by members of the Company's executive leadership team including Dr. Neil Fleshner, Chief Medical Officer, and Dr. Sherin Al-Safadi, VP Medical Affairs.

08:35 EDT Health Catalyst appoints Chief Medical and Chief Population Health Officers - Health Catalyst added Chief Medical Officer Melissa Welch and Chief Population Health Officer and Senior VP Edward Sheen to the executive leadership team. Welch will be the physician voice supporting new and current client growth-driving data-informed healthcare improvements across all areas of the business. Sheen will lead all value-based care initiatives and help Health Catalyst clients to advance their population health management journeys. Welch founded Perspectives of Differences Diversity Training and Consultation for Health Professionals. Sheen has worked with healthcare systems and payers in 25 states and held leadership roles across private, government, non-profit, and academic organizations.

08:35 EDT Mullen Automotive appoints Andre Hudson as VP, design - Mullen Automotive announces the hiring of Andre Hudson as its Vice President of Design. Prior to joining Mullen Automotive, he was the Head of Product Design at IndiEV.

08:33 EDT Sanuwave Health appoints Morgan Frank as board chairman - SANUWAVE Health announced the appointment of Mr. Morgan Frank as new Board Chairman effective today, August 5, 2022. Frank has been a principal at the life sciences focused investment fund Manchester Management since 2003 and a director of Manchester Explorer Cayman Ltd since 2013.Mr. Frank will succeed Mr. Kevin Richardson, who has served as Chairman since 2006. Mr. Richardson will remain CEO and continue to advise on key strategic initiatives as a Board Director along with Mr. Mike Stolarski, Mr. Jim Tyler, Mr. Ian Miller, and Mr. Jeffrey Blizard.

08:32 EDT GlobalFoundries, Qualcomm extend semiconductor manufacturing agreement - Following the recent passage of the U.S. CHIPS and Science Act last week, GlobalFoundries (GFS) and Qualcomm Technologies (QCOM) announced they are more than doubling their existing strategic global long-term semiconductor manufacturing agreement previously entered into by GF's and Qualcomm's respective subsidiaries. This announcement secures wafer supply and commitments to support U.S.-based manufacturing through capacity expansion at GF's most advanced semiconductor manufacturing facility, in Malta, New York. This announcement specifically extends QGT's U.S. based collaboration with GF in FinFET for 5G transceivers, Wi-Fi, Automotive and IoT connectivity. GF's FinFET platforms provide a best-in-class combination of performance, power and area that are well-suited for high-end Mobile, Automotive and IoT applications.

08:25 EDT A2Z Smart Technologies signs Statement of Work with Migros Ticaret - A2Z Smart Technologies announced has signed a Statement of Work's for it's Cust2Mate Smart Carts with Migros Ticaret, one of Turkey's leading grocery store chains, operating more than 1,000 locations nationwide. Pursuant to the SOW, Cust2Mate Smart Carts will be used at selected Migros locations in Turkey for a pilot trial. The Company anticipates that a successful pilot trial will lead to the launching of the smart carts across the Migros chain.

08:23 EDT Fluence Energy appoints Julian Nebreda as CEO, president - Fluence Energy (FLNC) announced that current board member Julian Nebreda will succeed Manuel Perez Dubuc as President and CEO of the Company, effective September 1, 2022. Nebreda has been a member of the Company's Board of Directors since September 2021. Most recently, Mr. Nebreda served as the Executive Vice President and President of US & Global Business Lines for The AES Corporation (AES). Dubuc will step down from his role as CEO, effective August 31, 2022 and is expected to resign as a director from the Board, effective August 31, 2022. Mr. Nebreda is expected to take office effective September 1, 2022, following a transition period with Mr. Perez Dubuc, to ensure a smooth handover. Mr. Nebreda will remain on the Company's Board.

08:20 EDT Plexus opens manufacturing facility in Bangkok, Thailand - Plexus announced the opening of its new advanced manufacturing facility in Bangkok, Thailand. The investment of more than $60 million to construct the 400,000 sq. ft. site, now a component of Plexus' network of 26 global facilities, signals a commitment to growth within the APAC region. The facility leverages energy efficient design, operational systems and monitoring elements in support of Plexus' Environmental, Social and Governance mission of building a better world by the way it innovates and operates.

08:18 EDT Kratos Defense receives $20M unmanned aerial drone system production contract - Kratos Defense & Security Solutions announced that it has received an approximate $20 million production contract for high performance, jet powered, unmanned aerial target drone systems. Kratos is an industry leader in the development, design and fielding of affordable, high-performance jet powered unmanned aerial drone systems. The unmanned aerial drone systems produced under this contract award will be manufactured in a Kratos production facility. Due to competitive, security-related, and other considerations, no additional information will be provided related to this award.

08:16 EDT Cerberus Cyber promotes Devoto to President - Cerberus Cyber Sentinel announces that Ashley Devoto has been appointed president of the company. She will continue to serve as chief information security officer, CISO, and remain responsible for guiding Cerberus Sentinel's global cybersecurity strategy as well as leading all cybersecurity operations and supporting the delivery of cybersecurity solutions to customers.

08:13 EDT Bombardier announces order for Challenger 3500 business jet - Bombardier announced the sale of its Challenger 3500 business jet to Italian-based operator, Air Corporate SRL. This will be the first company to offer the aircraft for charter in Europe.

08:12 EDT Seacoast Banking to acquire Professional Holding for $488.6M - Seacoast Banking (SBCF) and Professional Holding (PFHD), parent company of Professional Bank, announced that they have signed a definitive agreement under which Seacoast will acquire Professional. The proposed transaction will expand Seacoast's footprint in the dynamic tri-county South Florida market, which includes Miami-Dade, Broward, and Palm Beach Counties, the largest MSA in Florida and the eighth largest in the nation. Professional Bank, the sixth largest bank headquartered in South Florida, operates nine branches across Miami-Dade, Broward and Palm Beach counties, with deposits of approximately $2.4 billion and loans of $2.0 billion as of June 30, 2022. The proposed transaction is a natural continuation of Seacoast's M&A strategy, adding a premier franchise in one of Florida's fastest-growing markets. Under the terms of the acquisition agreement, Professional shareholders are to receive 0.8909 shares of Seacoast common stock for each share of Professional common stock. The exchange ratio for the transaction is fixed, which means that the transaction value will fluctuate as a result of changes in Seacoast's stock price. Based on Seacoast's closing price of $36.75 per share, as of August 5, 2022, the transaction is valued at approximately $488.6M. Closing of the transaction is expected in the first quarter of 2023, following receipt of approvals from regulatory authorities, required shareholder approvals, and the satisfaction of other customary closing conditions. Following completion of the transaction and system integrations, Professional Bank will operate as Seacoast Bank.

08:11 EDT Baker Hughes acquires Power Generation division of BRUSH group - Baker Hughes announced it has agreed to acquire the Power Generation division of BRUSH Group from One Equity Partners. This acquisition supports Baker Hughes' strategic commitment to lead in providing decarbonization solutions for the natural gas industry and historically hard-to-abate sectors. The addition of BRUSH will enhance Baker Hughes' core turbomachinery portfolio with electromechanical equipment, including electric generators, synchronous condensers, electric motors, and associated control power management systems. "We are delighted to bring the BRUSH Power Generation division, already a long-established and trusted supplier, into the Baker Hughes family," said Rod Christie, executive vice president of Turbomachinery & Process Solutions at Baker Hughes. "The need for electrification in the hard-to-abate and natural gas sectors plays an increasingly critical role in accelerating the path to net-zero. Through this acquisition, we will expand our core electrification capabilities and scope, further enhance our supply chain, and reach new industrial customers who can benefit from our broader turbomachinery and climate technology solutions offerings." BRUSH serves both commercial and industrial customers, including manufacturers, as well as energy producers, such as utility-scale power generators and upstream oil and gas producers. The acquisition provides an opportunity to leverage BRUSH's expertise and supply-chain to establish an electro-mechanical technology platform within Baker Hughes to serve a broad customer base with integrated solutions. The acquisition is expected to close in fourth quarter of 2022, upon receipt of all required customary regulatory approvals.

08:11 EDT Curaleaf names Ed Kremer as CFO, Camilo Lyon as CIO, Mitch Hara as CSO - Curaleaf Holdings has announced three new hires joining the company's executive leadership team this month. Ed Kremer will join as CFO, Camilo Lyon was named Chief Investment Officer, and Mitch Hara will be Chief Strategy Officer, a new role at the company. Kremer and Lyon will begin August 8 and Hara joined effective August 3. Newly appointed CFO Ed Kremer has most recently been working in the cannabis industry and brings a wealth of experience as a public CFO and leader at companies such as Oakley, Beats by Dre, and Oliver Peoples. Neil Davidson, Curaleaf's Interim CFO, will work closely with Mr. Kremer during the transition period. Camilo Lyon will lead Capital Markets and Investor Relations as Curaleaf's first Chief Investment Officer. Lyon most recently worked as a Managing Director at BTIG, where he covered the consumer and cannabis sectors. He brings over 20 years of finance experience and a wealth of knowledge and relationships to the role. In the newly created Chief Strategy Officer Role, Mitch Hara will oversee the company's strategy functions including mergers and acquisitions, international, and research and development. Hara brings years of experience as a seasoned strategist, operator, and dealmaker on Wall Street and in cannabis, most recently as Head of M&A and Business Development at Clever Leaves International.

08:09 EDT Tetra Technologies signs two exclusive technology licensing agreements - Tetra Technologies has entered into exclusive technology licensing agreements with KMX Technologies and Hyrec Holdings for the recycling of produced water for the purpose of beneficial reuse, including such applications as agricultural and crop irrigation, industrial, power generation, construction, groundwater recharge, cooling towers and dust control.

08:08 EDT Bit Digital announces July production update - Bit Digital announced its unaudited bitcoin and Ethereum production and corporate updates for the month of July. In July, the company earned 142.5 bitcoins, an 111% increase compared to the prior month. The company earned 0.5 ETH during July compared to 0.0 in the month ending June 30. Treasury holdings of BTC and ETH were 889.1 and 2,176.9, with a fair market value of approximately $20.7M and $3.7M, respectively, on July 31. The company owned 38,135 bitcoin miners and 731 Ethereum miners as of July 31, with an estimated maximum total hash rate of 2.7 Exahash and 0.3 Terahash, respectively. During the month, the company finalized an agreement for 5 megawatts of hosting capacity in Canada. The facility utilizes an energy source that is primarily hydroelectric. During the month of July, the company continued to work with hosting partners to deploy miners. 31% of its currently-owned fleet, or 12,044 bitcoin miners and 6 ETH miners representing 1.09 EH/s and 0.0 TH/s, respectively, was deployed in North America as of July 31.

08:05 EDT VolitionRx appoints Diagnostic Oncology CRO to spearhead U.S. FDA strategy - VolitionRx has appointed Diagnostic Oncology CRO to undertake development and clinical validation studies for its Nu.Q product portfolio in the United States. DXOCRO will conduct large-scale finding studies across multiple sites in the U.S. using Volition's Nu.Q NETs and Nu.Q Cancer tests to determine clinical utility in sepsis and cancer. Volition anticipates that subsequent studies will investigate the chosen intended use claims of the tests, with the objective to gain clearance, authorization, or approval from the United States FDA and allow the tests to be marketed in the U.S.

08:04 EDT Jack Henry names Mimi Carsley as CFO, succeeding Kevin Williams - Jack Henry & Associates (JKHY) announced that Mimi Carsley has been named as the company's CFO and treasurer, effective September 1. She will succeed Kevin Williams, who previously announced plans to retire. Williams will continue in his role until September 1, and will assist with the transition. Most recently, Carsley worked for Blucora (BCOR), a provider of data and technology-driven solutions that empower people to improve their financial wellness.

07:56 EDT Cenovus Energy acquiring 50% interest in Toledo refinery from BP - Cenovus Energy (CVE) has reached an agreement to purchase bp's (BP) 50% interest in the bp-Husky Toledo Refinery in Ohio. Cenovus has owned the other 50% of the refinery since its combination with Husky Energy in 2021. Cenovus's U.S. operating business will assume operatorship from bp upon closing of the transaction, which is expected before the end of 2022, dependent on the satisfaction of closing conditions. Total consideration includes $300 million in cash, subject to customary closing adjustments, plus the value of inventory. In addition, the parties have signed a multi-year product supply agreement. The transaction will give Cenovus an additional 80,000 barrels per day of downstream throughput capacity, including 45,000 bbls/d of heavy oil refining capacity. It will also provide the company with opportunities to further optimize its heavy oil value chain through integration with its upstream assets. Cenovus expects to realize synergies over the next few years as a result of the transaction, primarily related to the optimization of feedstock and refined product sales, and the longer-term potential to connect the Toledo Refinery with Cenovus's U.S. refining network. The Toledo Refinery recently completed a major, once in five years turnaround. Funded through the joint venture, the turnaround will improve operational reliability. This transaction will bring Cenovus's total refining capacity to 740,000 bbls/d.

07:49 EDT Tyson Foods targeting $1B+ in productivity gains by end of FY24 - Expects 40% of productivity gains to be delivered by the end of FY22, Tyson said in slides being presented on its Q3 earnings conference call.

07:45 EDT Ivanhoe Electric subsidiary reports diamond drilling results from San Matias - Ivanhoe Electric announced that Ivanhoe Electric's subsidiary, Cordoba Minerals has reported initial diamond drilling results from its ongoing drilling program at the San Matias Copper-Gold-Silver Project in Colombia. Ivanhoe Electric owns a 63.27% interest in Cordoba Minerals with the San Matias Copper-Gold-Silver Project itself being owned 100% by Cordoba Minerals. Highlights: 6,385 meters of the initial 25,000-meter in-fill drilling program have been completed within the Alacran Deposit. Significant assays returned to date include ACD087 - 61 meters with 0.99% copper, 0.35 g/t gold and 5.17 g/t silver or 1.17% copper equivalent; ACD097 - 53 meters with 0.70% copper, 0.70 g/t gold and 6.18 g/t silver or 1.11% CuEq 1. Mineralized intersections correlate closely with Cordoba Minerals' previously disclosed Pre-Feasibility Study Mineral Resource block model. Multiple late-mineral gold-copper veins, known as Carbonate Base Metal veins, have been intersected within drill holes and are superimposed upon high-grade zones of earlier carbonate replacement copper-gold mineralization. "We are excited to see the initial in-fill drill holes supporting the higher grade domains in the resource model for the Alacran Deposit. The fact that these domains also host multiple CBM veins brings Cordoba one step closer to understanding the relationship between the CBM and carbonate replacement events," commented Sarah Armstrong-Montoya, President and CEO of Cordoba. "Results indicate a shared feeder system for the mineralizing fluids and point towards excellent exploration potential to depth, including for a porphyry copper-gold source."

07:41 EDT Rezolve appoints Banerjjee global CEO of Products, Technology, Digital Services - Rezolve announced the appointment of Sauvik Banerjjee as the Company's global Chief Executive Officer, CEO, of Products, Technology, and Digital Services. Banerjjee brings to Rezolve more than 22 years of experience in senior roles in technology, digital product, and omni channel commerce. His most recent role was as the Chief Technology Officer and founding team member at Tata Digital and Tata Neu - The Super App - both being part of the 150-year-old conglomerate, Tata Group. December 17, 2021, Rezolve announced that it had entered into a definitive business combination agreement with Armada Acquisition Corp. I (AACI), a publicly-traded special purpose acquisition company. Upon closing of the transaction, the combined company's shares are expected to trade on the NASDAQ under the ticker symbol "ZONE".

07:41 EDT Williams and PennEnergy in pact for low emissions next gen natural gas - Williams and PennEnergy Resources an EnCap Investments portfolio company in the Appalachian Basin, announced they have entered into an agreement to support the marketing and delivery of certified, low emissions next gen natural gas. The agreement includes an independent, third-party certification process that verifies best practices are being followed to minimize emissions and produce natural gas in the most environmentally responsible manner. Through its Sequent business, Williams is building a marketing portfolio to sell low-carbon next gen gas to utilities, LNG export facilities and other clean energy users. "This is another exciting step in our multi-faceted strategy to grow the delivery of next gen gas to markets across the United States as well as overseas," said Chad Zamarin, senior vice president of Corporate Strategic Development for Williams. "With our large-scale gathering and processing footprint in the best U.S. production basins, our connectivity to the nation's biggest natural gas customers and our industry-leading Sequent marketing platform, we are extremely well positioned to facilitate the efficient gathering, marketing and transportation of responsibly sourced natural gas." "We are excited for this partnership and future opportunities to deliver responsibly sourced natural gas to meet the market's growing demands," said PennEnergy Resources Chairman and CEO Rich Weber. "PennEnergy welcomes higher standards in the marketplace, which play to our strengths, highlighting our dedication and investments made over many years to ensure the safety of our employees, the community and the environment." The Appalachian-sourced natural gas is derived from PennEnergy's 378 production wells in southwest Pennsylvania that have achieved Project Canary's TrustWell(TM) certification. Every well pad inspected achieved Platinum status, the highest rating available.

07:38 EDT Alpha Metallurgical provides 2022 operational guidance - "As a result of the European energy crisis caused by the Russian war, the thermal coal markets have shown significant volatility and increasing demand in recent months," said COO Jason Whitehead. "We fulfilled some customer requests for incremental thermal tonnage in Q2, which has pushed our expected total thermal volumes over the established guidance ranges for the year. Therefore, we are adjusting our shipment guidance to accommodate for these unique circumstances. Additionally, as a result of increased incentive compensation due to performance against budgeted metrics, we are increasing our guidance for selling, general and administrative expenses for the year." Alpha is increasing SG&A guidance to $55M-$59M, up from the prior range of $50M-$54M. The company is increasing its shipment guidance for thermal byproduct tonnage within the Met segment to a range of 1.0-1.4 million tons, up from prior guidance range of 0.8-1.2 million tons. This adjustment also slightly increases the total shipments guidance to a range of 15.6-17.2 million tons, up from prior range of 15.4-17.0 million tons. As of July 22, Alpha has committed and priced approximately 69% of its metallurgical coal within the Met segment at an average price of $260.69 per ton and 100% of thermal coal in the Met segment at an average expected price of $89.91 per ton. In the All Other category the company is 100% committed and priced at an average price of $83.38 per ton.

07:38 EDT Jushi Holdings settles lawsuit with Curaleaf - Jushi Holdings (JUSHF) announced that it entered into a confidential settlement agreement with Curaleaf Holdings (CURLF) and with Jushi's former Chief Financial Officer, Edward Kremer to resolve claims Jushi asserted in a lawsuit filed on July 15, 2022, including a claim asserted against Mr. Kremer for breach of his employment agreement and a claim asserted against Curaleaf for tortious interference. Under the terms of the settlement agreement: Mr. Kremer has reaffirmed and agreed to abide by his other continuing obligations to Jushi under the terms of his employment agreement in exchange for a limited waiver of his non-compete to allow him to accept employment with Curaleaf, and Curaleaf has made certain commitments to strengthen the commercial relationship between Jushi and Curaleaf.

07:35 EDT Zai Lab partner Karuna announces results from Phase 3 EMERGENT-2 trial - Zai Lab announced that the company's partner, Karuna Therapeutics, reported topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT, in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale total score compared to placebo at Week 5. KarXT also demonstrated an early and sustained statistically significant reduction of symptoms, as assessed by PANSS total score, starting at Week 2 and maintained such reduction through all timepoints in the trial. KarXT also met key secondary endpoints in the Phase 3 EMERGENT-2 trial, demonstrating a statistically significant reduction in both positive symptoms and negative symptoms of schizophrenia as measured by the PANSS positive, PANSS negative and PANSS negative Marder factor subscales. Results at Week 5 include: 2.9-point reduction in the PANSS positive subscale with KarXT compared to placebo; 1.8-point reduction in the PANSS negative subscale with KarXT compared to placebo; 2.2-point reduction in the PANSS negative Marder factor subscale with KarXT compared to placebo; KarXT was generally well tolerated. Overall discontinuation rates were similar between KarXT and placebo groups. The overall treatment-emergent adverse events rate for KarXT and placebo was 75% and 58%, respectively. Discontinuation rates related to TEAEs were similar between KarXT and placebo. Equal rates of serious TEAEs were observed between KarXT and placebo and included suicidal ideation, worsening of schizophrenia symptoms, and appendicitis. None of the serious TEAEs were determined to be drug related. The most common TEAEs in the KarXT arm were all mild to moderate in severity and included constipation, dyspepsia, nausea, vomiting, headache, increases in blood pressure, dizziness, gastroesophageal reflux disease, abdominal discomfort, and diarrhea. Mean blood pressure measures were similar between KarXT and placebo throughout the trial, and no syncopal events were observed. In the subset of patients with a TEAE of blood pressure increases, mean blood pressure at endpoint was similar to baseline and did not lead to trial discontinuation. Similar to prior trials, an increase in heart rate was associated with KarXT treatment and decreased in magnitude by the end of the trial. Consistent with EMERGENT-1, KarXT was not associated with common problematic side effects of current treatments, including sedation, weight gain, and extrapyramidal symptoms. The EMERGENT program consists of the completed positive Phase 2 EMERGENT-1 and Phase 3 EMERGENT-2 trials, as well as three ongoing trials evaluating the acute efficacy and long-term safety of KarXT. Topline data from the Phase 3 EMERGENT-3 trial are expected in the first quarter of 2023. The data from the EMERGENT program will be used to support submission of an NDA with the U.S. FDA for KarXT as a treatment for schizophrenia, which is expected in mid-2023. Additional analysis of data from the Phase 3 EMERGENT-2 trial is ongoing, with plans to present these results at future medical meetings.

07:30 EDT Renalytix announces study published in The American Journal of Managed Care - Renalytix announced the publication of a clinical utility study in The American Journal of Managed Care confirming Primary Care Physicians understand the value of KidneyIntelX in determining appropriate guideline-recommended treatment decisions in their adult patients with type 2 diabetes and early chronic kidney disease stages 1-3. The study of 401 geographically diverse clinicians was conducted by Boston Healthcare Associates, a third party specialized in medical device evaluation, clinical development, and data management. The published study complements recently published data from a real-world evidence clinical utility study of 1,112 adult DKD patients presented at the recent American Diabetes Association 82nd Scientific Sessions and the European Congress of Internal Medicine. These combined published results confirm the significant benefit of using KidneyIntelX in the Primary Care setting to direct care towards improving kidney health and reducing the significant financial burden associated with DKD. "The study publication announced today is a key element of a comprehensive evidence development program," said Tom McLain, President of Renalytix. "This program was designed to address the evidence requirements of payers, regulators, clinicians, and guideline setting bodies. The increasing volume of real-world evidence being generated from our health systems partnerships, presented at the ADA conference, confirms clinical utility, and indicates adoption of KidneyIntelX in the clinical setting." Results demonstrate growing awareness among PCPs in terms of the recognized value of KidneyIntelX in clinical decision making: The significance of these results was supported by a rigorous, analytical framework created to be highly representative of real-world care today and included 42 unique patient profiles and was designed to show what happens when KidneyIntelX is included vs. not included in patient care. The KidneyIntelX test had a greater relative importance than the standard of care for PCPs in prescribing guideline-recommended therapies and deciding when to consult with a specialist. 98% of PCPs responded they were somewhat, very, or extremely likely to use KidneyIntelX to predict which of their patients will experience rapid progressive kidney function decline. A behavioral shift among PCPs was examined after the introduction of KidneyIntelX. Approximately 80 percent of PCPs in the study noted risk assessment would support the decision to take more aggressive, guideline recommended clinical actions in high-risk, early stage diabetic kidney disease patients.

07:28 EDT Parsons, Aurora Insight partner to advance commercial space solutions - Parsons Corporation announced the addition of Aurora Insight as a strategic partner for commercial space research, development, and mission exploration and advancement. The multi-year agreement provides an agile vehicle where both companies can align their strengths and solutions with the goal of delivering affordable, rapid mission capabilities to U.S. national security and allied customers in the space domain. Aurora Insight, based in Colorado, directly measures the global radio frequency environment from a constellation of terrestrial and space-based sensor systems to provide government and commercial customers with comprehensive data on spectrum and wireless network infrastructure. "Our continued partnership with Aurora, who is equally focused on delivering innovative, rapid, affordable, operational space solutions will protect global security and transform all-domain operations for our warfighters," said Mike Kushin, Parsons' executive vice president of High Consequence Missions. "Aurora's innovative space-based RF capabilities paired with Parsons' mission-focused solutions are truly disruptive to the next generation of commercial space information warfare." Parsons and Aurora Insight successfully teamed on several efforts in the previous 18 months to advance access to RF spectrum information and to support the national security community in architecting the next generation of hybrid commercial and government space capabilities, bearing relevant results toward transformation of the all-domain battlespace. Both companies will focus their efforts on emerging defense need areas via disruptive application of more comprehensive data collection, algorithmic processing, data science, and analytic interpretation. The partnership will also develop new unconventional capabilities and methodologies that yield actionable intelligence delivered within tactically relevant timelines.

07:27 EDT Broadwind announces $35M credit facility - Broadwind announced that it has completed a $35 million senior secured asset-based revolving loan facility and a $7.578 million senior secured term loan facility with Wells Fargo Bank, National Association as lender. The five year facilities mature on August 4, 2027 and replace the Company's existing credit facility. The proceeds of the facilities will be used for general corporate purposes, including strategic growth opportunities.

07:26 EDT Stepstone Group closes fifth co-investment fund - StepStone Group announced the final closing of StepStone Capital Partners Fund V its fifth dedicated co-investment fund, raising $2.36 billion of commitments. Through SCP V, StepStone seeks to build a diversified portfolio of co-investments alongside leading private equity firms, in select transactions according to their areas of expertise. The Fund will invest in Buyout, Growth Equity, and Recapitalization transactions across a diverse set of managers, geographies, industries, vintage years, and sizes. A diverse group of sophisticated limited partners from around the world comprises the Fund's investor base.

07:24 EDT Agrify reaches agreement in principle with institutional lender - The Company has reached an agreement in principle with its institutional lender to amend its existing credit facility to modify certain financial covenants which, once complete, should give the Company additional flexibility to operate and meet its long-term strategic goals while also allowing it to responsibly adjust to the many challenges currently facing the cannabis industry.

07:22 EDT W&T Offshore sees 2022 total equivalents 14,450-15,450 MBoe

07:21 EDT CinCor Pharma announces upcoming milestones - Spark-PA: Phase 2 trial designed to evaluate the safety and efficacy of baxdrostat in patients with primary aldosteronism. Dosing of first patient expected in the third quarter of 2022; Topline data expected in the second half of 2023. HALO: Phase 2 trial designed to evaluate the safety and efficacy of baxdrostat in patients with uHTN. Topline data expected in the second half of 2022. figHTN-CKD: Phase 2 trial designed to evaluate the safety and efficacy of baxdrostat in patients with uHTN and CKD. Topline data expected in the second half of 2023

07:20 EDT W&T Offshore sees Q3 average daily equivalents 39-44 MBoe/d

07:19 EDT Stratasys to buy additive manufacturing materials unit of Covestro for EUR 43M - Stratasys announced it has signed a definitive agreement to acquire the additive manufacturing materials business of Covestro. The acquisition is expected to be immediately accretive upon closing. It will include R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and an IP portfolio comprised of hundreds of patents and patents pending. The purchase price is approximately 43M euros, plus additional inventory, less certain liabilities. In addition, there is a potential earnout of up to 37M euros, subject to the achievement of various performance metrics. The acquisition is expected to close during the first quarter of 2023, and the transaction is subject to the receipt of regulatory approvals and satisfaction of other customary closing conditions. The majority of employees of the acquired entity will continue to be based in Geleen, Netherlands and Elgin, Ill.

07:17 EDT KKR announces sale of Chicago industrial warehouse portfolio, no terms - KKR announced that KKR has sold a portfolio of distribution properties located in Chicago to a global investment manager. The portfolio consists of 13 assets with approximately 1.7M square feet of warehouse space and average clear heights of 24 feet. The properties are located in strategic infill locations across the Chicago metropolitan area. "We continue to see strong demand for well-located, last mile logistics real estate across Chicago," said Ben Brudney, a Director in the Real Estate group at KKR who oversees the firm's industrial investments in the United States. "We are very pleased to deliver this portfolio of high-quality assets to new owners who share our conviction in the market." KKR originally acquired the properties in December 2020 through its KKR Real Estate Partners Americas II fund. Across its funds, KKR has committed or acquired over $7B of U.S. logistics assets since 2018 and currently owns over 45 million SF of industrial real estate in strategic locations across major metropolitan areas nationwide.

07:14 EDT Uranium Energy and UEX Corp. announce amendment to arrangement agreement - Uranium Energy and UEX Corporation have entered into an amending agreement to the arrangement agreement dated June 13 as amended June 23, among UEX, UEC and the UEC 2022 Acquisition Corp., pursuant to which UEC will acquire all of the issued and outstanding common shares of UEX by way of a statutory plan of arrangement. Under the terms of the Amending Agreement, holders of UEX Shares will now receive 0.0890 of one common share of UEC for each UEX Share held, implying consideration of approximately C$0.49 per UEX Share based on the closing price of UEX Shares and UEC Shares on the TSX and the NYSE, respectively, and the spot exchange rate as of August 5. The Amending Agreement also increases the termination fee to be paid by UEX to UEC if the Transaction is terminated in certain specified circumstances by 7%. Other than the foregoing, the terms of the Transaction remain unamended. The Amending Agreement has been unanimously approved by the Board of Directors of UEX who continue to recommend that UEX Shareholders and holders of options and restricted share units of UEX vote in favor of the Transaction. The Amending Agreement has also been unanimously approved by the Board of Directors of UEC. If the UEX Securityholders approve the Arrangement at the Meeting, it is currently anticipated that the Arrangement will be completed in by mid-August, subject to obtaining court approval, stock exchange approval and certain required regulatory approvals, as well as the satisfaction or waiver of other conditions contained in the Arrangement Agreement. On completion of the Arrangement, former UEX Shareholders are expected to hold approximately 14.2% of the outstanding UEC Shares.

07:09 EDT Whirlpool confirms pact with Emerson Electric to acquire InSinkErator for $3B - Whirlpool (WHR) announced that it has entered into a definitive agreement with Emerson Electric (EMR) to acquire InSinkErator, the world's largest manufacturer of food waste disposers and instant hot water dispensers for home and commercial use, in an all-cash transaction for $3B. The acquisition is expected to be immediately accretive to Whirlpool Corporation's margins, adding approximately $1.25 EPS accretion in fiscal 2023. Whirlpool also expects to generate revenue upside by capitalizing on InSinkErator's leading consumer brand preference, an installed base that is fives times larger than the rest of the industry driving a recurring sales profile, the strong underlying secular tailwinds of the U.S. housing market, and the expansion of the InSinkErator brand into new markets and product offerings. Whirlpool plans to initially fund the acquisition through available liquidity, with new debt put in place at a later date. The acquisition, which has been approved by the Board of Directors of both companies, is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter. Whirlpool's 2022 guidance remains unchanged.

07:05 EDT Compugen: EPO grants new patent covering anti-PVRIG antibodies - Compugen announced that the European Patent Office has granted Compugen a new patent covering anti-PVRIG antibodies for use in cancer treatment. European Patent No. 3 653 221 link titled "Anti-PVRIG antibodies and Methods of Use" augments previously issued patents by expanding and protecting the use of COM701 for treating cancer patients, to include any anti-PVRIG antibody for use in the treatment of cancer, wherein the antibody activates T cells and/or NK cells and competes with COM701 for specific binding to PVRIG. The patent further claims such anti-PVRIG antibodies for use in the treatment of cancer, wherein the anti-PVRIG antibody is used in combination with antagonistic antibodies targeting additional immune checkpoints.

07:03 EDT Ceragon Networks board rejects Aviat Networks' revised indication of interest - Ceragon Networks (CRNT) issued the following letter to shareholders concerning the response of Ceragon's Board of Directors to the revised unsolicited, highly conditional, non-binding indication of interest from Aviat Networks (AVNW), a competitor of Ceragon. The letter states, in part, "A few days ago, Ceragon received a revised indication of interest from its competitor, Aviat Networks, to acquire Ceragon at a price of $3.08 per share. After a careful and thorough review, conducted in consultation with our independent financial and legal advisors, the Board unanimously concluded that Aviat's Revised IOI continues to significantly undervalue the company and is not in the best interests of Ceragon shareholders. "

06:58 EDT Benson Hill, Archer Daniels announce long-term strategic partnership - ADM (ADM) and Benson Hill (BHIL) announced a long-term strategic partnership to scale innovative soy ingredients that will help meet the rapidly growing demand for plant-based proteins. The partnership will serve a variety of plant-based food and beverage markets to meet savory, sweet and dairy customer needs. Through the collaboration, ADM will process and commercialize a portfolio of proprietary ingredients derived from Benson Hill Ultra-High Protein soybeans through an exclusive North American licensing partnership. The collaboration will scale innovative ingredients enabled by Benson Hill genetics that feature less-processed proteins with significant water and carbon sustainability benefits, representing an exciting new frontier in taste, texture, nutrition, and functionality for alternative protein solutions.

06:57 EDT Emerson Electric to sell InSinkErator business to Whirlpool for $3B - Emerson (EMR) announced an agreement to sell its InSinkErator business to Whirlpool Corporation (WHR) for $3B. InSinkErator's trailing twelve-month revenue, as of March 31, 2022, was $595M, pretax earnings were $148M and EBITDA was $166M, representing a transaction value of 18.1x EBITDA. The sale of InSinkErator represents a meaningful step in Emerson's continued commitment to creating a higher growth, more diversified and cohesive portfolio, the company said in a statement. The transaction is expected to close in Emerson's 2023 fiscal year, subject to regulatory approvals and other customary closing conditions. Emerson will work closely with Whirlpool Corporation to help ensure a smooth transition for customers and InSinkErator's nearly 1,400 employees, it said. Emerson engaged Goldman Sachs as its financial adviser and Davis Polk & Wardwell LLP as legal counsel for the transaction.

06:49 EDT Pfizer to acquire Global Blood Therapeutics for $68.50 per share in cash - Pfizer (PFE) and Global Blood Therapeutics (GBT) announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease. Under the terms of the transaction, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash, for a total enterprise value of approximately $5.4B, including debt and net of cash acquired. The Boards of Directors of both companies have unanimously approved the transaction. Pfizer expects to finance the transaction with existing cash on hand. The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by GBT's stockholders. Due to the proposed transaction, GBT will not hold its previously scheduled conference call to discuss its second quarter 2022 financial results. The company will file its quarterly report on Form 10-Q for the quarter ending June 30, 2022 with the U.S. SEC announcing those results on August 8.

06:46 EDT Pfizer to acquire Global Blood Therapeutics for $68.50 per share in cash

06:40 EDT Karuna Therapeutics says Phase 3 EMERGENT-2 trial met primary endpoint - Karuna Therapeutics announced positive topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT, in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale total score compared to placebo. KarXT also demonstrated an early and sustained statistically significant reduction of symptoms, as assessed by PANSS total score, starting at Week 2 and maintained such reduction through all timepoints in the trial. The company plans to submit a New Drug Application with the U.S. FDA in mid-2023.

06:33 EDT Denison Mines announces expiration of offer to acquire UEX Corporation - Denison Mines announced that its confidential offer to acquire UEX Corporation dated July 22 has expired.

06:11 EDT LMP Automotive enters asset sale pacts, to seek approval for plan of liquidation - LMP Automotive Holdings announced it has entered into dealership and real estate asset sale agreements to sell its Kia dealerships in Port Charlotte, FL, Cape Coral, FL and Beckley, WV, its Subaru dealership in Beckley, WW, its Chevrolet dealership in Beckley, WV and its General Motors dealership in Beckley, WV. The company anticipates that the expected closing of the sale will occur in October of this year, subject to the terms of the Agreements and numerous conditions precedent to Closing including but not limited to regulatory approval including any approval necessary under the Hart-Scott Rodino Antitrust Act. "We continue to believe that our stock price does not reflect the net asset value of our company and believe that this transaction along with the sale of our remaining assets will enable us to maximize stockholder value. The LMP Board of Directors unanimously recommends that at our next Special Meeting of Stockholders the company's stockholders vote to approve a proposed plan of liquidation of LMP's assets and the dissolution of the company. The Plan of Liquidation will allow the LMP Board to sell all of the company's assets, distribute the net proceeds to stockholders and dissolve the company. Importantly, the Plan of Liquidation will allow LMP to consummate the Sale of the above-mentioned assets and to enter into sales for its remaining assets not currently subject to sale agreements and to enter into value maximizing transactions without subjecting any such transaction to the delay and conditionality associated with having to seek and obtain stockholder approval." "The Board and the management team all believe that given the diversified nature of our portfolio, pursuing multiple transactions with different potential buyers for assets or groups of assets presents the best opportunity to maximize stockholder value," said Sam Tawfik, CEO and Chairman. "We believe that the Plan of Liquidation will maximize stockholder value as we continue to sell our remaining assets. Management believes that upon finalization of the Plan of Liquidation we expect that the company will be able to distribute aproximatly $115 million to $126 million to shareholders."

06:08 EDT BioNTech backs FY22 CapEx view EUR 450M- EUR 550M

06:06 EDT AstraZeneca, Hutchmed report results from SAVANNAH Phase II trial - Hutchmed (HCM) and AstraZeneca (AZN) announce that preliminary results from the SAVANNAH Phase II trial showed that TAGRISSO plus savolitinib demonstrated an objective response rate of 49% in patients with epidermal growth factor receptor-mutated non-small cell lung cancer with high levels of mesenchymal epithelial transition overexpression and/or amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on treatment with TAGRISSO. The highest ORR was observed in patients with high levels of MET who were not treated with prior chemotherapy. In patients whose tumors did not show high levels of MET, the ORR was 9%. These results are being shared at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer, taking place on August 6-9, 2022 in Vienna, Austria. Savolitinib, marketed in China under the brand name ORPATHYS, is an oral, potent and highly selective MET tyrosine kinase inhibitor being jointly developed and commercialized by AstraZeneca and Hutchmed .

05:46 EDT Carlyle Group CEO Kewsong Lee to step down, Bill Conway to be interim CEO - Carlyle Group announced changes in its executive leadership team. With CEO Kewsong Lee's five-year employment agreement coming to a close at the end of 2022, both the company's board of directors and Lee mutually agreed as part of their discussions that the timing is right to initiate a search for a new CEO to lead Carlyle forward in its next phase of growth. Lee will step down as CEO and a member of the board of directors. He will be available as needed to assist in a transition during the months ahead. The board has appointed William Conway, co-founder, current non-executive co-chairman of the board, and former co-CEO, to serve as interim CEO. A newly-formed search committee of the board will drive the search for a permanent successor. The board's search committee will include Conway as well as independent directors Lawton Fitt, Anthony Welters, Linda Filler, and Derica Rice. The board will immediately engage an executive search firm to identify and assess candidates for the permanent CEO position. Conway as he fulfills his duties as Interim CEO and assure a seamless transition once a permanent successor has been identified, an office of the CEO has been established. Peter Clare, chief investment officer for corporate private equity and chairman of Americas Private Equity, Mark Jenkins, Head of Global Credit, Ruulke Bagijn, Head of Global Investment Solutions, Curtis Buser, CFO, Christopher Finn, COO, and Bruce Larson, chief human resources officer, will comprise the office of the CEO and will work alongside Conway to continue driving forward Carlyle's strategy and build on the firm's strong momentum. To further facilitate a seamless transition, Finn has agreed to defer his previously-announced retirement at the end of this year. Consistent with its previously-reported second quarter earnings results, the company noted that, as of June 30, total assets under management was $376B, of which $260B was fee earning, and available capital for future investment was $81B. The company is again reaffirming its 2022 fee related earnings target of $850M, and its prior performance revenue guidance.

05:35 EDT BRP Inc. unveils first two models of its Can-Am all-electric motorcycle lineup - BRP Inc. announced that, in addition to working on electrifying its existing product lines, it is seizing opportunities to enter new markets with game-changing electric products. Today, BRP unveiled the first two models of its Can-Am all-electric motorcycle lineup, the Can-Am Origin and Can-Am Pulse. Building on its motorcycle legacy, BRP is changing the power dynamic and opening the road to a new generation of riders and electric vehicle enthusiasts. What's more, BRP is announcing a completely new electric hydrofoil board bearing the Sea-Doo signature - the Sea-Doo Rise. All three products will be available in mid-2024. BRP plans on revealing full specs in August 2023. For over 50 years, Sea-Doo has been transforming the personal watercraft industry, and more recently, the pontoon category. The brand sets out to democratize hydrofoiling. Offering different experiences and providing a variety of surfing positions for all skill levels.

05:29 EDT Accenture to acquire Romp - Accenture has agreed to acquire Romp, a brand and experience agency in Indonesia renowned for its creative talent and innovative services across branding, creative and performance marketing. The move will strengthen Accenture Song's ability to deliver creative and tech-driven brand experiences for clients across Southeast Asia. Founded in 2019, Romp's team of more than 150 people is behind breakthrough brand campaigns including Telkomsel's "Kuota Ketengan: Salute to Ketengers" that bagged a Best Creative Effectiveness Grand Prix at YouTube Works Awards 2021, Indofood/Indomie's "Where's the Noodle" that claimed a Gold award for Indonesia Cross-Channel Integration at SMARTIES 2021 and Bebelac's "Happy Trio" that cliched Campaign of the Year at the FMCG Asia Awards 2021. The award-winning team will join Accenture Song in Jakarta to jointly serve clients across consumer goods & services, telecoms and financial services industries and family-owned conglomerates. Terms of the transaction have not been disclosed. Completion of the acquisition is subject to customary closing conditions.

05:23 EDT UPS to acquire Bomi Group, terms undisclosed - UPS announced plans to acquire Bomi Group, a multinational healthcare logistics provider. The transaction will add temperature-controlled facilities in 14 countries and nearly 3,000 highly-skilled Bomi Group team members to the UPS Healthcare network in Europe and Latin America. Since 1985, Bomi Group has provided high value-added services for the Medtech and Pharma sectors with a customized and tailored approach. It is a quality-focused company devoted to healthcare that has built solid and long-lasting business relationships with more than 150 multinational customers worldwide. Key Bomi Group leaders, including CEO Marco Ruini, will continue in their roles to provide service to Bomi Group customers after the transaction closes. Bomi Group's employees will also continue to play roles in the combined organization. The acquisition will add more than 350 temperature-controlled vehicles and four million square feet to the UPS Healthcare global footprint, offering customers access to faster shipping times, greater production flexibility, and offerings to help them attract new business. The acquisition will play a key role in the delivery of next-generation pharmaceutical and biologic treatments that increasingly require time-critical and temperature-sensitive logistics. The acquisition of Bomi is part of UPS Healthcare's continued expansion of its network and services to meet growing demand - including Bomi, UPS Healthcare has doubled its global footprint since 2020. Recent expansions include newly constructed and soon-to-be-opened dedicated state-of-the-art healthcare logistics facilities in Germany and Australia, and expanded campuses in Hungary and the Netherlands. UPS Healthcare also recently enhanced UPS Premier, a technology-led service that can prioritize and track critical shipments within 10 feet of their location anywhere in UPS's global network. These expansions and new services meet the complex and varied needs of UPS Healthcare's customers, helping them turn logistics into a competitive advantage. The transaction is expected to close by the end of the year, subject to customary regulatory review and approval. The value and terms of the transaction are not being disclosed at this time.

05:14 EDT Diversey, LG Electronics enter exclusive distribution agreement - Diversey and LG Electronics announced that they have entered into an exclusive distribution agreement for LG's commercial washers and dryers in the UK and Ireland markets. This agreement offers customers across the region the opportunity to benefit from a wide range of innovative laundry equipment from the world's largest laundry machine manufacturer, combined with a fully-integrated suite of patented chemical solutions and engineering support; resulting in a 360 degree laundry program offered to shared customers.

05:08 EDT Matrix Service signs MoU with KOGAS to help development of hydrogen economy - Matrix Service announced that it has signed a memorandum of understanding, or MoU, with Korea Gas Corporation, or KOGAS, to support South Korea's development of a hydrogen economy as it transforms itself from a natural gas supplier to a hydrogen platform operator. The signing took place in Seoul with officials from both companies in attendance. The MoU provides the framework for the development of new technology to support onshore large-scale liquid hydrogen storage to support South Korea's plans to achieve carbon neutrality by 2050. The agreement also supports development of solutions that will allow transportation of greater volumes of hydrogen by transport ship.

05:02 EDT Arthur J. Gallagher acquires Another Day, terms undisclosed - Arthur J. Gallagher announced the acquisition of Another Day. Terms of the transaction were not disclosed. Founded in 2016, AnotherDay is a UK-based risk management consultancy, helping organizations across 90 countries pre-empt and prepare for complex threats, react to crises and investigate criminality through the use of intelligence and technology. The firm has worked with Gallagher since its inception providing clients with specialist risk management and crisis response services. The firm is headed up by Jake Hernandez who will continue to run the business.